Výsledky vyhledávání

Pharmacological discrimination of GluR5 and GluR6 kainate receptor subtypes by (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahyd roisdoquinoline-3 carboxylic-acid

Autor: Bleakman R, Dd, Schoepp, Ballyk B, Bufton H, Ef, Sharpe, Thomas K, Paul Ornstein, Rk, Kamboj

Publikováno v: Europe PubMed Central

The pharmacological tools available for the discrimination of kainate receptor subtypes are limited. We examined the effects of (3S,4aR,6R,8aR)-6-[2-(1(2)H-tetrazole-5-yl)ethyl]decahydr oisoquinoline-3-carboxylic acid (LY293558) and 2,3-dihydroxy-6-n

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::d79d9cf8934340aac86e4773f1725b75
https://pubmed.ncbi.nlm.nih.gov/8609884

Zobrazit plný text záznamu

Cyclothiazide acts at a site on the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid receptor complex that does not recognize competitive or noncompetitive AMPA receptor antagonists

Autor: Ma, Desai, Jp, Burnett, Paul Ornstein, Dd, Schoepp

Publikováno v: Europe PubMed Central

Activation of the alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) subtype of ionotropic glutamate receptors by certain agonists, including AMPA and glutamate, has been shown to result in a rapid desensitization of the receptor. This

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::4677aa310612edff786bbdda9859ff64
https://pubmed.ncbi.nlm.nih.gov/7529311

Zobrazit plný text záznamu

Pharmacological characterization of LY233053: a structurally novel tetrazole-substituted competitive N-methyl-D-aspartic acid antagonist with a short duration of action

Autor: Dd, Schoepp, Paul Ornstein, Jd, Leander, Lodge D, Cr, Salhoff, Zeman S, Dm, Zimmerman

Publikováno v: Europe PubMed Central

This study reports the activity of a structurally novel excitatory amino acid receptor antagonist, LY233053 [cis-(+-)-4-[(2H-tetrazol-5-yl)methyl]piperidine-2-carboxylic acid], the first tetrazole-containing competitive N-methyl-D-aspartic acid (NMDA

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::b33e91ad2447096f29828e2c07323de7
https://pubmed.ncbi.nlm.nih.gov/2148188

Zobrazit plný text záznamu

Neuroprotective effects of LY379268, a selective mGlu2/3 receptor agonist: investigations into possible mechanism of action in vivo

Autor: Bond A, Nm, Jones, Ca, Hicks, Gm, Whiffin, Ma, Ward, Neill Mf, O., Ae, Kingston, Ja, Monn, Paul Ornstein, Dd, Schoepp, Lodge D, Neill Mj, O.

Publikováno v: Europe PubMed Central

The mechanisms underlying the neuroprotective effects of the group II metabotropic glutamate receptor (mGluR) agonist LY379268 were investigated in a gerbil model of global ischemia. LY379268 (10 mg/kg i.p.) 30 or 60 min after 5-min bilateral carotid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::5315c04f03232f36ed5b4663e4447a27
http://europepmc.org/abstract/med/10945827

Zobrazit plný text záznamu

Akademický článek

mGlu2/3 receptor agonist (LY354740) in anxiety.

Autor: Schoepp DD; 128 Mill Creek Road, Ardmore, PA 19003, United States. Electronic address: darryle.schoepp@comcast.net.

Publikováno v: Pharmacology, biochemistry, and behavior [Pharmacol Biochem Behav] 2024 Sep; Vol. 242, pp. 173826. Date of Electronic Publication: 2024 Jul 18.

Zobrazit plný text záznamu

Akademický článek

Cortical influences of serotonin and glutamate on layer V pyramidal neurons.

Autor: Marek GJ; Astellas Pharma Global Development, Northbrook, IL, United States. Electronic address: gerard.marek@astellas.com., Schoepp DD; Consultant, Ardmore, PA, United States.

Publikováno v: Progress in brain research [Prog Brain Res] 2021; Vol. 261, pp. 341-378. Date of Electronic Publication: 2021 Jan 14.

Zobrazit plný text záznamu

Editorial & Opinion

Metabotropic glutamate receptors, 5 years on.

Autor: Collingridge GL; Department of Physiology, University of Toronto, Mount Sinai Hospital, Toronto, Canada; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital, Toronto, Canada; Centre for Synaptic Plasticity, School of Physiology, Pharmacology and Neuroscience, University of Bristol, Bristol, UK., Manahan-Vaughan D; Ruhr University Bochum, Medical Faculty, Department of Neurophysiology, Bochum, Germany., Nicoletti F; Department of Physiology and Pharmacology, University Sapienza of Roma, Italy; IRCCS Neuromed, Pozzilli, Italy. Electronic address: ferdinandonicoletti@hotmail.com., Schoepp DD; Merck Research Laboratories, Merck and Company, Inc., West Point, PA, USA.

Publikováno v: Neuropharmacology [Neuropharmacology] 2017 Mar 15; Vol. 115, pp. 1-3. Date of Electronic Publication: 2016 Nov 29.

Zobrazit plný text záznamu

Akademický článek

The Rapidly Acting Antidepressant Ketamine and the mGlu2/3 Receptor Antagonist LY341495 Rapidly Engage Dopaminergic Mood Circuits.

Autor: Witkin JM; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.) jwitkin@lilly.com., Monn JA; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.)., Schoepp DD; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.)., Li X; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.)., Overshiner C; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.)., Mitchell SN; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.)., Carter G; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.)., Johnson B; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.)., Rasmussen K; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.)., Rorick-Kehn LM; Departments of Neuroscience and Discovery Chemistry, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana (J.M.W., J.A.M., D.D.S., X.L., C.O., B.J., K.R., L.M.R.-K.), and Windlesham, Surrey, UK (S.N.M., G.C.).

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2016 Jul; Vol. 358 (1), pp. 71-82. Date of Electronic Publication: 2016 May 12.

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání